TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34404924

Group type: EXPERIMENTAL
Intervention: Low maternal education
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Maternal diabetes
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Neonatal brain injury
Number of subjects: 911

Group type: COMPARATOR
Intervention: Small for gestational age
Number of subjects: 911

Group type: COMPARATOR
Intervention: Weight <10th percentile at 36 weeks
Number of subjects: 911
Study: 34405140

Group type: EXPERIMENTAL
Intervention: Infusion of CD45RA memory T cells
Number of subjects: 0
Study: 34405312

Group type: EXPERIMENTAL
Intervention: Supported Employment Demonstration intervention
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Local economic characteristics (high unemployment rate, rising average wages)
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Qualitative reasons for enrollment
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Reasons for non-enrollment
Number of subjects: 2960

Group type: COMPARATOR
Intervention: Comparison of contacted vs. non-contacted samples
Number of subjects: 2960
Study: 34405577

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) at doses of 35 Gy, 37.5 Gy, 40 Gy, 42.5 Gy, and 45 Gy in five fractions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 16
Study: 34405965

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Hispanic
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: High volume enrollment (≥10 patients)
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Skin rash
Number of subjects: 1229
Study: 34406051

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34406122

Group type: EXPERIMENTAL
Intervention: Mom and Baby Net intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 184
Study: 34406124

Group type: EXPERIMENTAL
Intervention: Home-based connected devices (CDs) used for monitoring parameters, with education on reacting to abnormal variations; duration of intervention includes 3 months of data collection and 12 months of education and action plan development.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Educational program for patients and training for physicians; personalized action plans developed based on collected data and clinical history.
Number of subjects: 36
Study: 34406184

Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: CT-guided biopsy
Number of subjects: 1
Study: 34406372

Group type: EXPERIMENTAL
Intervention: ECLS patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High microembolic rate (>100/30 min) in ECLS patients
Number of subjects: 20
Study: 34406502

Group type: EXPERIMENTAL
Intervention: Topical low-dose (1,005 mg) preservative-free hydrocortisone, administered twice daily in each eye for 2 weeks.
Number of subjects: 100
Study: 34406524

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (non-hypoxemic patients)
Number of subjects: 51
Study: 34406537

Group type: EXPERIMENTAL
Intervention: Temporal lobe epilepsy patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Extra-temporal lobe epilepsy patients
Number of subjects: 90
Study: 34407054

Group type: EXPERIMENTAL
Intervention: Bevacizumab, carboplatin, and paclitaxel every 21 days for six cycles
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bevacizumab, carboplatin, and paclitaxel
Number of subjects: 54
Study: 34407260

Group type: EXPERIMENTAL
Intervention: 4 mm pen needles combined with education on injection technique
Number of subjects: 171
Study: 34407676

Group type: EXPERIMENTAL
Intervention: Silent cerebral infarcts and cerebral vessel stenosis on brain MRI and MRA
Number of subjects: 44
Study: 34407735

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin in combination with temsirolimus
Number of subjects: 19
Study: 34407844

Group type: EXPERIMENTAL
Intervention: M2698 monotherapy (15-380 mg daily)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: M2698/trastuzumab (160 mg QD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: M2698/tamoxifen (160 mg QD/240 mg intermittent regimen)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: M2698 (all cohorts)
Number of subjects: 101
Study: 34407840

Group type: EXPERIMENTAL
Intervention: Move to Health program, a holistic health intervention tailored for chronic low back pain, involving motivational interviewing and personal health inventory.
Number of subjects: 0
Study: 34407972

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA (therapeutic C/EBPα small activating RNA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA combined with checkpoint inhibitors or PMN-MDSC-targeted immunotherapy
Number of subjects: 36
Study: 34408044

Group type: EXPERIMENTAL
Intervention: Tai chi intervention (8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (booklet on self-management of cancer symptoms)
Number of subjects: 72
Study: 34408049

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antiviral treatment (Control)
Number of subjects: 0
Study: 34408155

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144
Study: 34408440

Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 34408662

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min cycling at 65% of heart rate reserve)
Number of subjects: 2
Study: 34408665

Group type: EXPERIMENTAL
Intervention: Auricular Neuromodulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34408750

Group type: EXPERIMENTAL
Intervention: 6B11-OCIK adoptive cell therapy (autologous T cells induced by 6B11 minibody plus dendritic cells and cytokines)
Number of subjects: 3
Study: 34408870

Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) and Near-Infrared (NIR) Fluorescence Imaging
Number of subjects: 0
Study: 34408978

Group type: EXPERIMENTAL
Intervention: Lymphocyte Doubling Time (LDT) >12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LDT ≤ 12 months
Number of subjects: 0
Study: 34409288

Group type: EXPERIMENTAL
Intervention: 1MIU low-dose interleukin-2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2MIU low-dose interleukin-2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34409513

Group type: EXPERIMENTAL
Intervention: OptiBP™ (test method)
Number of subjects: 110
Study: 34409593

Group type: EXPERIMENTAL
Intervention: ACEI or ARBs treatment
Number of subjects: 5837

Group type: COMPARATOR
Intervention: No ACEI or ARBs treatment
Number of subjects: 5837

Group type: EXPERIMENTAL
Intervention: Presence of arterial hypertension
Number of subjects: 5837

Group type: EXPERIMENTAL
Intervention: ACEI or ARBs treatment at discharge
Number of subjects: 5837

Group type: EXPERIMENTAL
Intervention: Antiviral drugs, interferon treatment, oral anticoagulation at discharge
Number of subjects: 5837
Study: 34409776

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg D1 and Apatinib 250 mg D1-21 for a 21-day cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Number of subjects: 0
Study: 34409850

Group type: EXPERIMENTAL
Intervention: Nanoparticle ablation and cryoablation of the prostate using a novel automated three-dimensional surgical planning tool and MRI/ultrasound fusion technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34410545

Group type: EXPERIMENTAL
Intervention: CTC+ patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: CTC- patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARFL+ patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARFL- patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC and ARFL expression detected
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARV7, PSMA and PSA expression on CTC
Number of subjects: 0
Study: 34410757

Group type: EXPERIMENTAL
Intervention: Postconcussion symptoms
Number of subjects: 84
Study: 34410791

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 80
Study: 34410793

Group type: EXPERIMENTAL
Intervention: Minority Stress Experiences and Interactions (MSEI) coding scheme
Number of subjects: 19
Study: 34411009

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous racemic ketamine
Number of subjects: 10
Study: 34411499

Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR)
Number of subjects: 40
Study: 34411630

Group type: EXPERIMENTAL
Intervention: Capnography (ETCO2) as a trend monitor
Number of subjects: 116
Study: 34412498

Group type: EXPERIMENTAL
Intervention: Platelet count <20×10^9/L
Number of subjects: 3939

Group type: EXPERIMENTAL
Intervention: Platelet count decrease
Number of subjects: 3939

Group type: EXPERIMENTAL
Intervention: Normal platelet count range
Number of subjects: 3939
Study: 34412512

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with intravenous thrombolysis
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy without thrombolysis
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Successful recanalization
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: CAA diagnosis
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale score
Number of subjects: 162
Study: 34412682

Group type: EXPERIMENTAL
Intervention: Camostat tablets, 200 mg four times daily (qds) for 14 days
Number of subjects: 389

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 389
Study: 34412687

Group type: EXPERIMENTAL
Intervention: Oral estradiol for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 86
Study: 34412696

Group type: EXPERIMENTAL
Intervention: I-SLEEP intervention (educational video, brochure, sleep kit, and questions to ask providers)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: I-SLEEP intervention
Number of subjects: 37
Study: 34412795

Group type: EXPERIMENTAL
Intervention: QFR pull back pressure gradient index
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Instantaneous QFR gradient per unit length
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI physiological results
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of target vessel failure (TVF) after PCI
Number of subjects: 341
Study: 34412800

Group type: EXPERIMENTAL
Intervention: Fluoroscopic Guidance
Number of subjects: 0
Study: 34412811

Group type: EXPERIMENTAL
Intervention: 29-biomarker panel
Number of subjects: 748
Study: 34413097

Group type: EXPERIMENTAL
Intervention: Ladnaan intervention (culturally tailored parenting support programme)
Number of subjects: 51
Study: 34413106

Group type: EXPERIMENTAL
Intervention: Web-based self-administered health-related data collection system
Number of subjects: 0
Study: 34413145

Group type: EXPERIMENTAL
Intervention: CD8-targeted PET imaging
Number of subjects: 0
Study: 34413166

Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (group 1, mCSCC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (group 2, locally advanced CSCC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (group 3, mCSCC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cemiplimab (all groups)
Number of subjects: 193
Study: 34413210

Group type: EXPERIMENTAL
Intervention: High-dose inhaled nitric oxide (INO) at 160 ppm for 15 min twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electric NO (eNO) generator at 160 ppm for 15 min twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressurized nitrogen/NO cylinders (INO) at 160 ppm for 15 min twice daily
Number of subjects: 12
Study: 34413249

Group type: EXPERIMENTAL
Intervention: Respiratory treatment
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Readmission for respiratory cause
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Overall readmissions
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Factors associated with readmission
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Factors associated with respiratory treatment
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Respiratory morbidity
Number of subjects: 1287
Study: 34413768

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34413804

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 0
Study: 34414218

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34414292

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 498
Study: 34414517

Group type: EXPERIMENTAL
Intervention: Gynaecological cancer survivors with gastrointestinal syndromes
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Blood discharge syndrome
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Urgency syndrome
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Leakage syndrome
Number of subjects: 247

Group type: COMPARATOR
Intervention: Survivors without radiation-induced survivorship syndromes
Number of subjects: 247
Study: 34414532

Group type: EXPERIMENTAL
Intervention: Ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and monthly goserelin/leuprolide in men and pre-/perimenopausal women
Number of subjects: 3246
Study: 34414777

Group type: EXPERIMENTAL
Intervention: Multi-gene pharmacogenetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34414843

Group type: EXPERIMENTAL
Intervention: Tafasitamab plus idelalisib (cohort A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tafasitamab plus venetoclax (cohort B)
Number of subjects: 24
Study: 34414986

Group type: EXPERIMENTAL
Intervention: Online questionnaire study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical observational study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle imaging (muscle ultrasound and whole-body MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunological studies (in vitro stimulation with toll-like receptor ligands)
Number of subjects: 0
Study: 34415049

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination (2 doses for HSCT patients)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 135
Study: 34415114

Group type: EXPERIMENTAL
Intervention: MINT therapy (wearable myoelectric interface)
Number of subjects: 23
Study: 34415222

Group type: EXPERIMENTAL
Intervention: Turkish version of the Physical Activity Scale for Individuals with Physical Disabilities (PASIPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Turkish version of the PASIPD
Number of subjects: 0
Study: 34415225

Group type: EXPERIMENTAL
Intervention: Activities Scale for Kids performance (ASKp)
Number of subjects: 206
Study: 34415365

Group type: EXPERIMENTAL
Intervention: Dial method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cylinder method
Number of subjects: 72
Study: 34415964

Group type: EXPERIMENTAL
Intervention: Cohort 1 (received standard dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cohort 2 (received higher first dose and fractional fifth dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cohort 2 (fractional fifth dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Post-4th and post-5th responses in protected subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: IFN-γ and IL2 responses to TRAP, CelTOS, and CSP
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Peripheral IFN-γ, IL2, and IFN-γ+IL2 responses
Number of subjects: 2
Study: 34416075

Group type: EXPERIMENTAL
Intervention: ImAgeS predictive score based on a reduced Elastic Net model
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: 28-day fatality rate
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Factors associated with reduced risk of death
Number of subjects: 1379
Study: 34416158

Group type: EXPERIMENTAL
Intervention: Lenvatinib with etoposide plus ifosfamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 34416160

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents combined with systemic chemotherapy
Number of subjects: 0
Study: 34416167

Group type: EXPERIMENTAL
Intervention: PD-1/L1 therapy followed by MAPK inhibitors (MAPKi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAPK inhibitors (MAPKi)
Number of subjects: 0
Study: 34416175

Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (300 mg/day) initiated between 28-32 weeks of gestation and continued through 12 weeks postpartum.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: 0.5 mL) administered within 24 hours of life.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Study procedures and acceptability of the intervention.
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment or vaccination (control group not explicitly mentioned).
Number of subjects: 90
Study: 34416218

Group type: EXPERIMENTAL
Intervention: FEV (Forced Expiratory Volume) measurement
Number of subjects: 2998
Study: 34416758

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not provided)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patients reaching remission (MADRS ≤ 10)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Patients (MDD)
Number of subjects: 129
Study: 34416849

Group type: EXPERIMENTAL
Intervention: Goal management training before a healthy lifestyle program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy lifestyle program alone
Number of subjects: 100
Study: 34416867

Group type: EXPERIMENTAL
Intervention: On-site HCV screening and case management services
Number of subjects: 441
Study: 34417144

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Trametinib and panitumumab
Number of subjects: 14

Group type: COMPARATOR
Intervention: Historical control data (panitumumab alone)
Number of subjects: 14
Study: 34417162

Group type: EXPERIMENTAL
Intervention: PNT2258 120 mg/m intravenously
Number of subjects: 13
Study: 34417212

Group type: EXPERIMENTAL
Intervention: Glutathione S-transferase-π (GST-π)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Peroxiredoxin 1 (PRDX1)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Combination of GST-π and PRDX1
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Performance of biomarkers within 3-hour and 6-hour windows
Number of subjects: 945
Study: 34417217

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (ICBT)
Number of subjects: 228
Study: 34417223

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in mothers
Number of subjects: 73
Study: 34417415

Group type: EXPERIMENTAL
Intervention: PNE+E (Pain Neuroscience Education plus Exercise)
Number of subjects: 61

Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 61
Study: 34417444

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
Number of subjects: 38
Study: 34417620

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness intervention
Number of subjects: 0
Study: 34417635

Group type: EXPERIMENTAL
Intervention: Peer-led healthy lifestyle intervention
Number of subjects: 155
Study: 34417675

Group type: EXPERIMENTAL
Intervention: Veliparib 30 to 40 mg twice daily on days 1 to 7 with concurrent temozolomide 150 mg/m²
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Veliparib and temozolomide
Number of subjects: 62
Study: 34417688

Group type: COMPARATOR
Intervention: Muscle architecture assessment in pwMS using ultrasonography
Number of subjects: 33

Group type: COMPARATOR
Intervention: Muscle strength assessment in pwMS using a digital hand-held dynamometer
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison of muscle strength in different MS subtypes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation analysis in pwMS
Number of subjects: 33
Study: 34417735

Group type: COMPARATOR
Intervention: golimumab-IV
Number of subjects: 833
Study: 34417859

Group type: EXPERIMENTAL
Intervention: Good mental health profile (26%)
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Intermediate mental health profile (68%)
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Poor mental health profile (6%)
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: Higher levels of well-being
Number of subjects: 3767
Study: 34417919

Group type: EXPERIMENTAL
Intervention: Lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline)
Number of subjects: 2860

Group type: EXPERIMENTAL
Intervention: Maximum lactate concentration on day 1
Number of subjects: 2860

Group type: EXPERIMENTAL
Intervention: Decreasing lactate concentration over time (∆ serum lactate)
Number of subjects: 2860
Study: 34417990

Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 135
Study: 34418086

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco) administered 4390 times for 3853 seizure clusters
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco)
Number of subjects: 163